This is a notion that can be translated to explain previous clinical studies that showed not every diabetic patient with breast cancer can benefit from metformin treatment, only those who have HER2 positive tumors since HER2 is correlated with metabolism through the activation of the downstream signaling of Akt [6]. This evidence concerns the gene ERBB2 and breast cancer.